scholarly journals INTESTINAL MICROBIOCENOSIS AND CYTOKINE STATUS IN LUNG CANCER PATIENTS RECEIVING CHEMOTHERAPY

2017 ◽  
Vol 20 (3) ◽  
pp. 152-157
Author(s):  
Margarita Yu. Serkova ◽  
E. B Avalueva ◽  
I. G Bakulin ◽  
S. I Sitkin
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Intestinal Microflora ◽  
Control Group ◽  
Gas Liquid Chromatography ◽  
Lung Cancer Patients ◽  
Before And After ◽  
Oncological Diseases ◽  
Intestinal Microbiocenosis

In patients with oncological diseases chemotherapy leads to the damage of a mucous membrane of gastrointestinal tract, as well as to a deterioration of the intestinal microbiocenosis. The article presents the changes in intestinal microbiocenosis in lung cancer patients, chemotherapy, the nature of the influence appointed in the schemes of the treatment of lung cancer, impact of anticancer drugs on the state of the intestinal microflora, and the improvement of technologies of treatment of lung cancer patients receiving chemotherapy on the basis of supplementation of the complex therapy by the probiotics Material and methods. 41 lung cancer patient receiving the first line of the first cycle of chemotherapy was included. The age of patients varied from 49 to 73 years, the average duration of the disease was 1 year. Patients from the main group (n = 21) received probiotics treatment together with the chemotherapy course. Patients from the control group (n = 20) received only chemotherapeutic preparations. All patients were observed before and after treatment, the study of metabolites of intestinal microorganisms in blood was performed by the method of the gas-liquid chromatography - mass-spectrometry by G.A. Osipov’s method, determination of cytokine status multiplex method. The efficiency of probiotic therapy was evaluated by results of the dynamics of studied indices. Results. The deterioration in intestinal microflora was manifested as the decreased quantity of Lactobacillus, Bifidobacterium, and increased quantity of different pathogenic microorganisms. It was noted decreased rate in the improvement of composition intestinal microflora after the treatment course with the metabiotic. Conclusion. Using of metabiotic medicines with the chemotherapy in lung cancer patients is promising to prevent deterioration of the gut microflora.

scholarly journals miRNA-486 and miRNA-499 in human plasma evaluate the clinical stages of lung cancer and play a role as a tumor suppressor in lung tumorigeneisis not pathogenesis

2016 ◽  
Vol 11 (1) ◽  
pp. 264 ◽  
Author(s):  
Youchao Jia ◽  
Aimin Zang ◽  
Yanguang Feng ◽  
Xiao-Fang Li ◽  
Ke Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Statistical Significance ◽  
Small Cell ◽  
Expression Level ◽  
Control Group ◽  
Small Cell Lung ◽  
Lung Cancer Patients

<p class="Abstract">It was aimed to explore the expression level of miRNA-486 and miRNA-499 in the plasma of lung cancer patients and analysis their differences in expre-ssion. The expression level of both miRNA-486 and miRNA-499 in the plasma of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) were lower than that of the control group (p&lt;0.05) and the decrease was more obvious in NSCLC. Compare with the miRNA-499，expression quantity in NSCLC patients plasma. There was statistical significance difference (p&lt;0.05) between III～Ⅳstage and I～II stage. The expression quantity of miRNA in plasma of patients with extensive-stage SCLC was lower than that of patients with limited-stage SCLC (p&lt;0.05). The sensitivity and specificity of plasms miRNA-486 respectively were 88.5% and 83.3%. The expression of miRNA-499 and miRNA-486 in lung cancer patients were up-regulated, and might be closely related to the occurrence and prognosis of lung cancer, and might be used as potential screening and prognosis index for lung cancer.</p><p> </p>

scholarly journals Effect of respiratory training apparatus and vibration expectoration vest on expectoration in patients with lung cancer resection

2018 ◽  
Vol 5 (4) ◽  
pp. 285-289
Author(s):  
Xiao-Jing Guo ◽  
Li-Li Wei ◽  
Xin-Hui Li ◽  
Ning- Ning Yu ◽  
Shao-Bo Gao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Respiratory Function ◽  
Perioperative Period ◽  
Control Group ◽  
Observation Group ◽  
Pulmonary Atelectasis ◽  
Cancer Resection ◽  
Lung Cancer Patients ◽  
Respiratory Training

Abstract Objective The aim of this study was to explore the safe and effective method of expectoration in the preoperative period of patients with lung cancer resection and to promote the rehabilitation of patients. Methods A total of 100 cases of lung cancer patients undergoing elective surgery were divided into the observation group and the control group, with 50 cases in each group. The control group was treated with vibration expectoration vest for expectoration during the perioperative period, and the observation group was treated with respiratory function exerciser that has expectoration function in the perioperative period, three times a day, and the effect was evaluated after 5 days. Results The number of patients in the observation group after the first expectoration time was significantly less than that of the control group (P<0.001). Pain score, pulmonary atelectasis, and pulmonary infection rate of the observation group were significantly lower than those of the control group; the hospitalization time was significantly shorter than that of the control group; and the difference was statistically significant (P<0.05). Conclusions Lobectomy for lung cancer patients with perioperative respiratory training for respiratory function exercise, compared with conventional methods, is helpful for postoperative expectoration and to reduce the incidence of adverse events.

Microarray study of gene expression profiles in peripheral blood samples from lung cancer patients before and after erlotinib treatment

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19072-e19072
Author(s):  
A. Irigoyen ◽  
C. Olmedo ◽  
J. Valdivia ◽  
A. Comino ◽  
C. Cano ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Growth Factor ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Peripheral Blood ◽  
Expression Profiles ◽  
Control Group ◽  
Blood Samples ◽  
Lung Cancer Patients

e19072 Background: The gene expression profile in peripheral blood samples from lung cancer patients is a potential predictor to treatment response. Methods: The study has been developed using 10 healthy volunteers as the control group and 10 lung cancer patients (stage IV). Written informed consent was obtained being the protocol approved by the local Clinical Research and Ethics Committee. Peripheral blood samples were obtained from lung cancer patients before (T0) and after treatment (T15d). RNA from peripheral blood samples was extracted and purified selecting 28S/18S ratios>1.5 to obtain cDNA and cRNA for hybridization of the 20,000 genes included in Human 20K CodeLink. An array from each participant was obtained in duplicate. For each array, 2 μg of cRNA was compared to 2 μg of healthy cRNA.. Significant genes were found using Significance Analysis of Microarrays which uses repeated permutations of the data. Results: The selected genes were expressed >3-fold with a false discovery rate =0.05. Before treatment (T0) when patients were compared to healthy volunteers there was an increase in the expression of: histone 1 H4c, transforming growth factor beta 2, endothelial cell growth factor 1 (platelet-derived), glucose-6-phosphatase catalytic 2, Relaxin 3 receptor 1, Insulin-like growth factor binding protein 2, RAS-like family 11 member B, and ELK4. After treatment (T15d), when each lung cancer patient's results were compared to their own before treatment results (T0), there was an increase in the expression of: Bcl2, myosin light polypeptide 4; interferon alpha-inducible protein 27; interferon gamma receptor 1; RASSF5, ARHGEF6, IGFBP5, tumor protein p53 inducible nuclear protein 1, peroxisome proliferative activated receptor gamma. Conclusions: The data presented identifies biologically relevant over-expressed genes in lung cancer. A validation of these results and the analysis of the genes that identify patients who will respond positively to erlotinib treatment is being carried out. No significant financial relationships to disclose.

Anti-dementia and anti-hyperlipidemic medication use at end of life in elderly lung cancer patients: Analysis of SEER-Medicare data.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10027-10027 ◽  
Author(s):  
Min Ji Kim ◽  
Zhigang Duan ◽  
Hui Zhao ◽  
Holly Michelle Holmes ◽  
Joanna-Grace Mayo Manzano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Use ◽  
End Of Life ◽  
Cancer Patients ◽  
Cholesterol Absorption ◽  
Study Endpoint ◽  
Lung Cancer Patients ◽  
Bile Acid Sequestrants ◽  
Before And After ◽  
Hospice Use

10027 Background: Despite risk for polypharmacy, elderly cancer patients may receive drugs whose time to benefit likely exceeds life expectancy. This study aims to describe use of drugs considered potentially unnecessary, namely anti-hyperlipidemics and anti-dementia drugs, and to identify factors associated with their use in Stage 3 or 4 non-small cell lung cancer (NSCLC) patients approaching end of life. Methods: We identified all patients older than 65 diagnosed with primary Stage 3 or 4 NSCLC between 2006 and 2011 in the Surveillance, Epidemiology and End Results (SEER)-Medicare database. Information on drug prescriptions was extracted from Medicare Part D files. First-time hospice enrollment or death date was used as the final endpoint in analysis. The primary outcome was use of drugs of interest at 4 months before NSCLC diagnosis, 6 months and 3 months before death or hospice. Associations with demographic or other factors were tested using the Pearson χ2 test. Results: Of all 7983 patients, 45.1% were taking statins before diagnosis, while 40.7% and 30.9% were still taking statins at 6 and 3 months before death or hospice. Use of bile acid sequestrants, fibric acid derivatives, and cholesterol absorption inhibitors were found to decrease toward death or hospice. In contrast, anti-dementia drug use did not decrease, with 3.4% before diagnosis and 4.2% and 3.5% at 6 and 3 months before death or hospice. Approximately 30% of anti-dementia medications were newly prescribed at 6 and 3 months before study endpoint. Having a higher number of prescriptions at 3 months before death or hospice was associated with higher rates of drug use both before and after cancer diagnosis. Having a higher Charlson comorbidity index correlated with greater anti-dementia drug use before diagnosis. Demographic, socioeconomic, and treatment factors were not found to be correlated with drug use. Conclusions: A high prevalence of statin use persists while a notable proportion of anti-dementia drugs are newly prescribed toward death or hospice. Our findings suggest an opportunity for clinicians to re-evaluate risks and benefits of potentially unnecessary medications in elderly patients nearing end of life.

Brain metastasis in lung cancer: Are there any predictive risk factors?

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21740-e21740
Author(s):  
Salma Ait Batahar
Keyword(s):  
Lung Cancer ◽  
Brain Metastasis ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Control Group ◽  
Lung Cancer Patients ◽  
Poorly Differentiated Carcinoma ◽  
Poorly Differentiated ◽  
The Mean ◽  
The Moment

e21740 Background: Lung cancer is the first cause of death by cancer worldwide. Brain metastases in lung cancer are associated to an even poorer prognosis of this cancer. Identifying patients with a higher risk of developing brain cancer may help their prognosis by including systematic brain radiotherapy to their treatment. But what are risk factors of brain metastasis occurrence in lung cancer patients? Methods: To answer this question, we conducted a case control study comparing two groups of lung cancer patients. The cases group included 35 lung cancer patients with brain metastasis at the moment of diagnosis while the control group was made of 49 lung cancer patient with no brain metastasis at the moment of diagnosis. Many parameters were compared between the two groups such as: professional exposure, type and duration of smoking, medical history, clinical and radiological presentation as well as the histological type of the carcinoma. Results: The mean age was 56 for the cases group and 61 for the control group. Nonsmokers represented 14% in the cases group and 4% in the control group. The average smoking was 34 pack-year for the cases group and 31 pack-year for the control group and in both groups 51% of patients smoked a mixture of tobacco and Cannabis. 36% of the control group patients had an exposure to a professional carcinogen while 48% of the cases group patients had one. Digital clubbing was found in 62% of cases group patients and in 51% of the control group patients. 17% of the cases group patients had two more metastases outside the lungs and other than the brain ones while this rate was only 6% for the control group patients. The mean level of LDH (Lactate Dehydrogenase) was 340 U/L for the cases group and 342 U/L for the control group while the CRP (C- reactive protein) one was 78 mg/L for the cases group and 59 mg/L for the control group. The main histological type found in both groups was Adenocarcinoma (25% in the cases group and 18% in the control group) followed by the poorly differentiated carcinoma in the cases group and the squamous cell carcinoma in the control group. Small cell carcinoma was found in 5% of the patients with brain metastases and in 8% of the patients without brain metastases. Conclusions: Patients with brain metastases have a higher professional carcinogens exposure, a higher percentage of nonsmokers, more digital clubbing, and higher CRP levels than patients with no brain metastases. They also have more than one metastasis at the moment of the diagnosis and the predominant histological types are Adenocarcinoma and poorly differentiated carcinoma.

Sign in / Sign up

Export Citation Format

Share Document